Please assess the completion status of the following clinical trial:

Trial Title: Effect of Albumin Administration on Vasopressor Duration in Resolving Septic Shock

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years of age or older who meet the clinical criteria for septic shock~   a. Presence of two or more of the following: i. A core temp ≥38C or ≤36C; ii. A heart rate ≥90 beats/min; iii. A respiratory rate ≥ 20 breaths/min or PaCO2 ≤32mmHg or use of mechanical ventilation for an acute process; iv. A white blood cell count ≥12000/ml or ≤4000/ml or immature neutrophils \> 10%.~   b. Presence of defined (or suspected) site of infection as show by at least one of the following criteria: i. An organism grown in blood or sterile site; ii. An abscess or portion of infected tissue; iii. Suspected infection despite culture growth by the attending physician. c. Infusion of vasopressors is required to maintain blood pressure~2. Vasopressor requirements~   a. Patients can be considered for study inclusion when his/her vasopressor requirements are as follows: i. Norepinephrine 0.04-0.25 mcg/kg/min (plus or minus vasopressin) OR phenylephrine 0.2-2 mcg/kg/min (plus or minus vasopressin) AND ii. Last measured lactate value was \< 4 mmol/L AND iii. The patient is on stable or decreasing doses of vasopressors for 8 hours or more. This 8 hour measurement will start at the maximum amount of vasopressor support within the range defined in i. above.~3. Serum albumin level \<2.5g/dl. The level must be drawn within the last 24 hours of Time=0.~Exclusion Criteria:~1. Patients \<18 years old~2. Albumin administration 24 hours prior to the time of enrollment (Time=0)~3. Prisoners~4. Terminal state~5. Known adverse reaction to albumin administration~6. Pregnancy~7. Pathological conditions in which albumin administration is clinically indicated (hepatic cirrhosis with ascites, hepatorenal syndrome, intestinal malabsorption syndrome, nephrotic syndrome, burns)~8. Patients with acute liver failure or cirrhosis~9. Patients on continuous renal replacement therapy~10. Patients who are morbidly obese ≥40kg/m2~11. Religious objection to the administration of human blood products.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 25% Albumin (Type: EXPERIMENTAL): 25% albumin 75 grams IV over 1 hour once.
- Placebo (Type: PLACEBO_COMPARATOR): 0.9% normal saline 200mL IV over 1 hour once.

Based on this trial design, predict the completion outcome and termination type (if applicable).